KR20140032944A - 항폴레이트 수용체 알파 항체 당형태 - Google Patents

항폴레이트 수용체 알파 항체 당형태 Download PDF

Info

Publication number
KR20140032944A
KR20140032944A KR1020137012669A KR20137012669A KR20140032944A KR 20140032944 A KR20140032944 A KR 20140032944A KR 1020137012669 A KR1020137012669 A KR 1020137012669A KR 20137012669 A KR20137012669 A KR 20137012669A KR 20140032944 A KR20140032944 A KR 20140032944A
Authority
KR
South Korea
Prior art keywords
fra
amino acid
seq
acid sequence
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
KR1020137012669A
Other languages
English (en)
Korean (ko)
Inventor
필립 엠. 사스
니콜라스 니콜라이데스
루이기 그라쏘
에릭 루티어
웨이 구
제이슨 영
준 야오
Original Assignee
모르포테크, 인크.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 모르포테크, 인크. filed Critical 모르포테크, 인크.
Publication of KR20140032944A publication Critical patent/KR20140032944A/ko
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
KR1020137012669A 2010-10-20 2011-10-19 항폴레이트 수용체 알파 항체 당형태 Withdrawn KR20140032944A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US39481210P 2010-10-20 2010-10-20
US61/394,812 2010-10-20
PCT/US2011/056966 WO2012054654A2 (en) 2010-10-20 2011-10-19 Anti-folate receptor alpha antibody glycoforms

Publications (1)

Publication Number Publication Date
KR20140032944A true KR20140032944A (ko) 2014-03-17

Family

ID=45975873

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020137012669A Withdrawn KR20140032944A (ko) 2010-10-20 2011-10-19 항폴레이트 수용체 알파 항체 당형태

Country Status (12)

Country Link
US (1) US20120164137A1 (https=)
EP (1) EP2629798A4 (https=)
JP (1) JP2014505012A (https=)
KR (1) KR20140032944A (https=)
CN (1) CN103347537A (https=)
AU (2) AU2011317088B2 (https=)
BR (1) BR112013009275A2 (https=)
CA (1) CA2815080A1 (https=)
IL (1) IL225579A0 (https=)
MX (1) MX2013004202A (https=)
RU (1) RU2013122843A (https=)
WO (1) WO2012054654A2 (https=)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2172487A1 (en) * 2005-04-22 2010-04-07 Morphotek Inc. Antibodies with Immune Effector Activity that Internalize in Folate Receptor Alpha-Positive Cells
US9512223B2 (en) * 2012-05-15 2016-12-06 Morphotek, Inc. Methods for treatment of gastric cancer
HUE049693T2 (hu) * 2012-08-31 2020-10-28 Immunogen Inc Diagnosztikai ASSAY-k és készletek a folát receptor 1 kimutatására
JP6224619B2 (ja) * 2012-12-07 2017-11-01 協和発酵キリン株式会社 抗ｆｏｌｒ１抗体
US8956830B2 (en) 2013-03-14 2015-02-17 Momenta Pharmaceuticals, Inc. Methods of cell culture
US9217168B2 (en) 2013-03-14 2015-12-22 Momenta Pharmaceuticals, Inc. Methods of cell culture
US20140271622A1 (en) * 2013-03-14 2014-09-18 Momenta Pharmaceuticals, Inc. Methods of cell culture
TWI771890B (zh) 2013-03-14 2022-07-21 美商安美基公司 用於增加重組蛋白質之甘露糖含量之方法
US9677105B2 (en) 2013-03-14 2017-06-13 Momenta Pharmaceuticals, Inc. Methods of cell culture
AU2014312086B2 (en) 2013-08-30 2020-03-12 Immunogen, Inc. Antibodies and assays for detection of folate receptor 1
EP2871190A1 (en) * 2013-11-11 2015-05-13 ATLAB Pharma Antibody against GD2-O-acetylated ganglioside with pro-apoptotic activity
RS61010B1 (sr) 2014-11-20 2020-11-30 Hoffmann La Roche Bispecifični antigen vezujući molekuli koji aktiviraju t ćelije protiv folr1 i cd3
DK3221355T3 (da) 2014-11-20 2020-12-07 Hoffmann La Roche Kombinationsbehandling med T-celleaktiverende bispecifikke antigenbindende molekyler CD3 og folatreceptor 1 (FolR1) samt PD-1-aksebindende antagonister
SI3221357T1 (sl) 2014-11-20 2020-09-30 F. Hoffmann-La Roche Ag Pogoste lahke verige in načini uporabe
ES2784503T3 (es) 2014-12-01 2020-09-28 Amgen Inc Procedimiento para manipular el nivel de contenido de glicano de una glicoproteína
AU2016323968B2 (en) 2015-09-17 2023-07-06 Immunogen, Inc. Therapeutic combinations comprising anti-FOLR1 immunoconjugates
CN115925952A (zh) 2018-03-13 2023-04-07 东莞凡恩世生物医药有限公司 抗叶酸受体1抗体及其用途
KR102275930B1 (ko) * 2018-03-14 2021-07-12 (주)알테오젠 Folr1에 특이적으로 결합하는 항체 및 그의 용도
CN118344485B (zh) * 2024-06-18 2024-10-15 南京欧凯生物科技有限公司 抗叶酸及其结合蛋白复合物的单克隆抗体或其抗原结合片段、其制备方法及应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2004261229A1 (en) * 2003-07-29 2005-02-10 Eisai, Inc. Antibodies and methods for generating genetically altered antibodies with enhanced effector function
CA2556027C (en) * 2004-02-12 2015-11-24 Morphotek, Inc. Monoclonal antibodies that specifically block biological activity of a tumor antigen
PL1776384T3 (pl) * 2004-08-04 2013-10-31 Mentrik Biotech Llc WARIANTY REGIONÓW Fc
ZA200708694B (en) * 2005-04-15 2009-01-28 Immunogen Inc Elimination of heterogeneous or mixed cell population in tumors
EP2172487A1 (en) * 2005-04-22 2010-04-07 Morphotek Inc. Antibodies with Immune Effector Activity that Internalize in Folate Receptor Alpha-Positive Cells
CN101374546B (zh) * 2005-12-16 2016-03-23 Ibc医药公司 基于免疫球蛋白的多价生物活性装配体
WO2011116387A1 (en) * 2010-03-19 2011-09-22 Tetragenetics, Inc. Production of aglycosylated monoclonal antibodies in ciliates

Also Published As

Publication number Publication date
JP2014505012A (ja) 2014-02-27
WO2012054654A2 (en) 2012-04-26
CN103347537A (zh) 2013-10-09
BR112013009275A2 (pt) 2017-06-20
IL225579A0 (en) 2013-06-27
AU2011317088A1 (en) 2013-05-02
AU2016202082A1 (en) 2016-04-28
US20120164137A1 (en) 2012-06-28
MX2013004202A (es) 2013-10-17
CA2815080A1 (en) 2012-04-26
EP2629798A2 (en) 2013-08-28
RU2013122843A (ru) 2014-11-27
WO2012054654A3 (en) 2012-08-02
AU2011317088B2 (en) 2016-01-21
EP2629798A4 (en) 2014-05-28

Similar Documents

Publication Publication Date Title
KR20140032944A (ko) 항폴레이트 수용체 알파 항체 당형태
CN108650886B (zh) 多价和多特异性gitr-结合融合蛋白
CN107148430B (zh) 抗tigit抗体
RU2733315C2 (ru) Комбинированная терапия для лечения злокачественной опухоли
CN112424358B (zh) 与细胞粘附分子3结合的抗体
TW200817436A (en) Antigen binding molecules that bind EGRF, vectors encoding same, and uses thereof
KR20190042037A (ko) 항-tim-3 항체 및 그의 용도
KR20190028534A (ko) 항 gprc5d 항체, gprc5d 및 cd3에 결합하는 이중특이성 항원 결합 분자, 및 이들의 용도
KR20190004319A (ko) Cd40l-fc 융합 폴리펩티드 및 이의 사용 방법
EA037882B1 (ru) Агонистические антитела, специфически связывающие человеческий cd40, и способы их применения
KR102921110B1 (ko) 항체-약물 접합체 및 이의 용도
KR20160067978A (ko) Ｖｅｇｆ 길항제와 항-ｃｔｌａ-4 항체의 조합물을 포함하는 조성물 및 방법
WO2021023108A1 (zh) 一种抗pd-1抗体及其医药用途
EP4674868A1 (en) Fap/4-1bb/cd40 binding molecule and medicinal use thereof
CN114057877A (zh) 抗pd-l1抗体及其应用
KR102916382B1 (ko) 항-cldn-18.2 항체 및 그 용도
TW202330027A (zh) 抗ｃｄ－４７抗體製劑
KR20230154981A (ko) 항-인간 cxcr5 항체 및 이의 용도
RU2829997C1 (ru) Антитело к cldn-18.2 и его применение
HK40069234A (en) Anti -pd-l1 antibody and use thereof
HK40047612A (en) Antibody binding to cell adhesion molecule 3
HK40055449A (en) Novel anti-cd4 antibodies
HK40048585A (en) Anti-her2/pd1 bispecific antibody

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20130516

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
PC1203 Withdrawal of no request for examination
WITN Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid